Skip to main content

Table 2 Point estimates, 95 % confidence intervals and distributions of fitted parameters

From: Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study

Parameter

Point estimate

95 % CI

Distribution

q, low transmission

1.88 e−3

1.224 e−3, 2.217 e−3

Non-parametric

q, moderate transmission

30.50 e−3

19.222 e−3, 37.682 e−3

Non-parametric

q, high transmission

184.8 e−3

87.972 e−3, 272.147 e−3

Non-parametric

Probability of full immunity, r imm

1.97 %

1.93 %, 2.17 %

Non-parametric

Age-related susceptibility factor, k

1.58 e−2

1.02 e−2, 3.63 e−2

Non-parametric

Waning of acquired immunity, w

0

  

Probability of asymptomatic infection

 a1

8.57 %

0.29, 17.79 %

Non-parametric

 a2

38.49 %

7.74, 43.62 %

Non-parametric

 a3

38.58 %

7.94, 43.82 %

Non-parametric

 a4

38.68 %

8.37, 43.93 %

Non-parametric

 a5

38.90 %

15.65, 44.12 %

Non-parametric

 a6

54.19 %

25.87, 61.82 %

Non-parametric

Percentage of clinical cases that become severe with good access to care

 f1

2.40 %

1.19, 5,46 %

Non-parametric

 f2

2.13 %

1.19, 3.04 %

Non-parametric

 f3

2.13 %

1.19, 3.03 %

Non-parametric

 f4

2.05 %

1.19, 2.92 %

Non-parametric

 f5

1.99 %

1.19, 2.92 %

Non-parametric

 f6

1.33 %

0.96, 2.12 %

Non-parametric

Vaccine parameters

   

 Vaccine efficacy in infants aged 6–12 weeks

37.6 %

35.53, 41.11 %

Log-normal

 Half-life in infants aged 6–12 weeks (months)

6.2

3.3, 11.7

Log-normal

 Vaccine efficacy in children aged 5–17 months

58.2 %

56.5, 59.6 %

Log-normal

 Half-life in children aged 5–17 months (months)

14.4

10.6, 19.2

Log-normal